RepliCel Life Sciences Inc. is developing autologous cell therapies to treat conditions including chronic tendon injuries, pattern baldness and UV damaged and aging skin. All products are based on RepliCel s innovative technology which utilizes cells isolated from a patient s healthy hair follicles. Specific cells are isolated, replicated, and delivered back into the patient. In , RepliCel completed three phase clinical studies including RCH for pattern baldness from Androgenetic Alopecia, RCT for chronic Achilles tendinosis, and RCS for aging and UV damaged skin. All trials successfully met their primary endpoints and provided significantly positive clinical efficacy data on secondary endpoints. Shiseido Company, the fourth largest cosmetics company in the world, has an exclusive geographic license for RCH in certain Asian countries including Japan, China, and South Korea. They are funding a clinical study in Japan. RepliCel is actively engaging potential partners for its other products. In addition to its cellular products, RepliCel has also developed a proprietary, next generation dermal injection device RCI . The device is designed for optimal delivery of RCH and RCS but represents a next gen dermal injector for use with other dermatological injection procedures.
Quote | RepliCel Life Sciences (OTCMKTS:REPCF)
Last: | $0.042835 |
---|---|
Change Percent: | 0.0% |
Open: | $0.042835 |
Close: | $0.042835 |
High: | $0.042835 |
Low: | $0.042835 |
Volume: | 550 |
Last Trade Date Time: | 03/15/2024 03:00:00 am |
News | RepliCel Life Sciences (OTCMKTS:REPCF)
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developi...
Independent Testing Performed by Innovacell Demonstrates the DermaPrecise ™ Control Leads to Unparalleled Post-Injection Cell Survival and Viability Consistency VANCOUVER, BC / ACCESSWIRE / August 2, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliC...
Message Board Posts | RepliCel Life Sciences (OTCMKTS:REPCF)
Subject | By | Source | When |
---|---|---|---|
Check out $MYMX, an M&A potential target in | Trend-Setter | investorshub | 10/17/2018 3:53:58 PM |
Yup! Mymetics Corp. ($MYMX), a swiss based public | Trend-Setter | investorshub | 10/17/2018 3:51:02 PM |
There are 2...AMF$ and MGCL#. One Canadian, the | rushmann | investorshub | 10/14/2018 6:10:00 PM |
Which is the other company. Thanks! I'm letting | XBRIANX | investorshub | 10/14/2018 3:58:41 PM |
There are many sleepers among the 10k+ OTC | rushmann | investorshub | 10/13/2018 5:26:51 PM |
News, Short Squeeze, Breakout and More Instantly...
RepliCel Life Sciences Company Name:
REPCF Stock Symbol:
OTCMKTS Market:
RepliCel Life Sciences Website:
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developi...
Independent Testing Performed by Innovacell Demonstrates the DermaPrecise ™ Control Leads to Unparalleled Post-Injection Cell Survival and Viability Consistency VANCOUVER, BC / ACCESSWIRE / August 2, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliC...
After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell therapy products VANCOUVER, BC / ACCESSWIRE / July 28, 2022 / RepliCel Life Sciences ...